Park West Asset Management LLC Purchases New Stake in Elanco Animal Health Incorporated $ELAN

Park West Asset Management LLC acquired a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the 2nd quarter, Holdings Channel reports. The firm acquired 1,015,000 shares of the company’s stock, valued at approximately $24,979,000. Elanco Animal Health comprises approximately 1.7% of Park West Asset Management LLC’s holdings, making the stock its 25th biggest holding.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Parallel Advisors LLC increased its holdings in Elanco Animal Health by 5.9% in the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock valued at $160,000 after purchasing an additional 392 shares in the last quarter. Sapient Capital LLC raised its holdings in shares of Elanco Animal Health by 0.3% during the 2nd quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after buying an additional 420 shares during the period. Lazard Asset Management LLC lifted its position in Elanco Animal Health by 0.6% during the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after acquiring an additional 425 shares in the last quarter. Northwestern Mutual Investment Management Company LLC boosted its holdings in Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after acquiring an additional 428 shares during the period. Finally, Meeder Advisory Services Inc. grew its position in Elanco Animal Health by 4.8% in the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock valued at $254,000 after acquiring an additional 510 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Insiders Place Their Bets

In other news, Director Lawrence Erik Kurzius purchased 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The stock was bought at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the acquisition, the director owned 188,647 shares in the company, valued at $4,414,339.80. The trade was a 26.91% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul Herendeen acquired 10,000 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the transaction, the director owned 111,687 shares in the company, valued at $2,644,748.16. The trade was a 9.83% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have purchased 63,198 shares of company stock worth $1,473,109. 1.14% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ELAN. JPMorgan Chase & Co. upped their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 22nd. Piper Sandler restated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Citigroup increased their target price on Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, KeyCorp lifted their price target on shares of Elanco Animal Health from $29.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Stock Performance

Elanco Animal Health stock opened at $25.09 on Thursday. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a 12 month low of $17.11 and a 12 month high of $27.98. The company has a fifty day moving average price of $24.61 and a two-hundred day moving average price of $24.01. The company has a market cap of $12.54 billion, a PE ratio of -61.20, a P/E/G ratio of 1.50 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The business had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.26 EPS. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Research analysts expect that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.